TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15124080
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of test substances in the UVB erythema model
Study: 3511207
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered arginine free base 1 to 2 mmol/kg/day for 2 months (n = 13)
Study: 3511207
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (n = 12)
Study: 31386891
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg EMEND® capsules
Study: 31386891
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg EMEND® capsules
Study: 24401221
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (RSV10/EZE10 or RSV20/EZE10)
Study: 10882628
Drug: Mebendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (200 mg twice a day for 10 days)
Study: 10882628
Drug: Thiabendazole (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiabendazole (25 mg/kg twice a day for 10 days)
Study: 10882628
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg initially, then 200 mg daily for 10 days)
Study: 8936542
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg.kg‐1
Study: 8936542
Drug: Vecuronium 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.16 mg.kg‐1 and Mivacurium 0.2 mg.kg‐1 (V2M2)
Study: 8936542
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg.kg‐1 and Mivacurium 0.1 mg.kg‐1 (V1M1)
Study: 26940798
Drug: Traditional outpatient
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional outpatient physical therapy
Study: 25608899
Drug: 30 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg/d mNGF by intramuscular injection for two courses (4 weeks for each course) with a 15-day interval
Study: 25608899
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza Bunge and deproteinized extract of calf blood, methylcobalamin tablets, and vitamin B6
Study: 12562651
Drug: GEM (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM (1000 mg/m(2)) on days 1 and 8 and CBDCA (AUC 5 mg.min/ml) on day 1, 4 h before GEM (arm A)
Study: 12562651
Drug: GEM (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM (1000 mg/m(2)) on days 1 and 8 and CBDCA (AUC 5 mg.min/ml) on day 1, 4 h after GEM (arm B)
Study: 2007323
Drug: Nalmefene 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 25 mg orally
Study: 2007323
Drug: Nalmefene 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 50 mg orally
Study: 2007323
Drug: Nalmefene 100
Normalized name: nalmefene 100 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 100 mg orally
Study: 2007323
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg intramuscularly
Study: 2007323
Drug: Morphine 30
Normalized name: ethylmorphine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 30 mg intramuscularly
Study: 28003205
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g freeze-dried strawberry powder added to a high-fat meal (50 g total fat)
Study: 18799887
Drug: Betadine vaginal
Normalized name: Betadine Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadine vaginal preparation (not washed out)
Study: 12849673
Drug: Picotamide (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (a renal TxA(2) synthase and TxA(2)/prostaglandin H(2) receptor inhibitor)
Study: 10458353
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin E1 gel plus 5% SEPA
Study: 8911260
Drug: Comprehensive broad-spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive broad-spectrum empirical antimicrobial therapy (imipenem and cilastatin sodium, 500 mg, intravenously, every 6 hours)
Study: 8911260
Drug: Limited-spectrum empirical
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited-spectrum empirical antimicrobial therapy (cefoxitin sodium, 2 g, intravenously, every 6 hours)
Study: 31050933
Drug: Diode Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode Laser (DL) as an adjunct to Kirkland flap surgery
Study: 28314755
Drug: Allopurinol dose
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol dose escalation for 12 months; increased monthly until SU <6 mg/dL.
Study: 28314755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continuing current dose of allopurinol.
Study: 28314755
Drug: Allopurinol dose
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol dose escalation group.
Study: 15065473
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual Control group
Study: 11320542
Drug: NSAID administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID administered 3 doses during 24 hours before surgery
Study: 11320542
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered
Study: 7907668
Drug: Deliberate increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deliberate increase of oxygen delivery index to greater than 600 mL/min per square meter using dopexamine hydrochloride infusion
Study: 29522362
Drug: ADT+D (androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT+D (androgen deprivation therapy with docetaxel)
Study: 29522362
Drug: ADT (androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT (androgen deprivation therapy alone)
Study: 23491524
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ticagrelor twice daily
Study: 23491524
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prasugrel once daily
Study: 10755205
Drug: Rescue thrombolysis
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue thrombolysis with rTPA 50 mg (10 mg bolus + 40 mg in 60 minutes)
Study: 9103739
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training treatment group (PT)
Study: 3003317
Drug: Citrate-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-containing oral rehydration solution
Study: 28367952
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (2.5 mg/d folic acid, 50 mg/d vitamin B6, 1 mg/d vitamin B12)
Study: 9754894
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin) with or without TED stockings
Study: 8132702
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg coumarin and cimetidine daily
Study: 8132702
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g coumarin daily
Study: 8132702
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g coumarin daily
Study: 3043033
Drug: Cefbuperazone (CBPZ)
Normalized name: cefbuperazone
DrugBank: Cefbuperazone (DB13638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefbuperazone (CBPZ) 4 g/day
Study: 3043033
Drug: Cefbuperazone (CBPZ)
Normalized name: cefbuperazone
DrugBank: Cefbuperazone (DB13638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefbuperazone (CBPZ) 2 g/day
Study: 1473409
Drug: Oral gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gentamicin and metronidazole for two days
Study: 1473409
Drug: Combined (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (oral + i.v.) gentamicin and metronidazole
Study: 26047892
Drug: Esmirtazapine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine (both doses)
Study: 21451509
Drug: CCX354 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX354 100 mg single dose
Study: 21451509
Drug: CCX354 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX354 300 mg single dose
Study: 21451509
Drug: CCX354 1-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX354 1-300 mg/day oral doses
Study: 16622646
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (600 mg/day during chemotherapy and 3 months after cessation)
Study: 15228804
Drug: robot training
Approvals — FDA: no, EMA: no, PMDA: no
Description: robot training plus conventional therapy
Study: 2927483
Drug: Trimethoprim-sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160 mg and 800 mg, given orally four times a day for 10 days, then 160 mg and 800 mg three times a week)
Study: 2927483
Drug: Sulfadoxine and
Normalized name: Sulfadoxine and Pyrimethamine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine and pyrimethamine (500 mg and 25 mg weekly)
Study: 24689695
Drug: Nurse-guided, basal-prandial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-guided, basal-prandial insulin treatment protocol (NGP)
Study: 24689695
Drug: Physician-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-guided therapy (PGT)
Study: 21401358
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 18 months
Study: 16571155
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of trans-11-18:1 (tVA) and 3 g/d of trans-12-18:1 (t12)
Study: 12846896
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (r‐EPO) at a single, weekly dose of 40,000 U for at least 8 weeks
Study: 7528126
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs in add-on trials
Study: 7528126
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs in monotherapy designs
Study: 30702538
Drug: Individualized opioid
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized opioid dosing protocol for VOE management
Study: 30702538
Drug: Weight-based opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based opioid dosing protocol for VOE management
Study: 25692556
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm long implants (test group)
Study: 25692556
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm long implants (control group)
Study: 25692556
Drug: Both 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 6 mm and 10 mm implants
Study: 22343119
Drug: Immediate-postoperative isophane
Normalized name: insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl
Study: 22343119
Drug: Standard-of-care control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care control group (short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl)
Study: 17503748
Drug: AI system
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI system for estimating drug exposure and interpreting pharmacokinetic data for LPV
Study: 17503748
Drug: AI system
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI system for estimating drug exposure and interpreting pharmacokinetic data for EFV
Study: 11592603
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (9 million units three times per week) and lamivudine (100 mg/daily) for 24 weeks
Study: 11592603
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg/daily) for 52 weeks
Study: 11592603
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b and lamivudine combination therapy
Study: 9538976
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LP) and Human regular insulin (HR)
Study: 2116086
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium (0.6 mg/kg per day in four intravenous doses)
Study: 30578048
Drug: RECELL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECELL treatment (combined with widely meshed STSG)
Study: 30578048
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (standard meshed STSG)
Study: 30578048
Drug: RECELL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECELL treatment
Study: 30578048
Drug: RECELL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECELL treatment and Control treatment
Study: 23981511
Drug: Minocycline (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (25-100 mg daily based on weight)
Study: 20137620
Drug: Zenapax (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zenapax (induction therapy)
Study: 20137620
Drug: Regular immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular immunosuppressive therapy (control group)
Study: 15012174
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin (CsA) with mycophenolate mofetil (2g daily) and prednisone (0.5-1 mg/kg daily)
Study: 11404230
Drug: Gaboxadol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol (15 mg)
Study: 9331118
Drug: Neoadjuvant paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant paclitaxel (200 mg/m2/3 hour, day 1) and carboplatin (AUC 5, day 2)
Study: 2010565
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (8 g for 21 days)
Study: 2010565
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (identical-looking capsules for 21 days)
Study: 27729164
Drug: Preemptive intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive intra-articular 20 mL of bupivacaine 0.5% injection
Study: 27729164
Drug: Preemptive periacetabular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive periacetabular 20 mL of bupivacaine 0.5% injection
Study: 27729164
Drug: Total analgesic
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total analgesic consumption
Study: 12870691
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of antituberculosis chemotherapy
Study: 9175240
Drug: Pectin supplement
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin supplement (15 g/day)
Study: 4002804
Drug: Muzolimine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muzolimine (20 mg per day)
Study: 29609926
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Group (LDG): Two 90-min yoga classes plus three 30-min homework sessions weekly for 12 weeks.
Study: 29609926
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Group (HDG): Three 90-min yoga classes plus four 30-min homework sessions weekly for 12 weeks.
Study: 15101859
Drug: Morphine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (50 micro g kg(‐1) loading dose, followed by intravenous morphine-PCA)
Study: 15101859
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (1 mg of morphine)
Study: 2882060
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for 4 weeks)
Study: 29548304
Drug: Coordinated medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated medication management model (CoMM) involving practical nurses and clinical pharmacists
Study: 29548304
Drug: Community pharmacists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacists conducting medication reviews
Study: 29548304
Drug: Implementation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation and follow-up of medication changes
Study: 28473063
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein (HP) diet (1.5 g•kg‐1•d‐1 protein)
Study: 28473063
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (0.8 g•kg‐1•d‐1 protein)
Study: 23340711
Drug: Web-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychosocial treatment
Study: 16481707
Drug: 1% lindane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lindane cream
Study: 12582352
Drug: Single-dose clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose clindamycin (600 mg)
Study: 12582352
Drug: 24-hour clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour clindamycin prophylaxis (600 mg total)
Study: 9337609
Drug: Typical daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical daily dose of caffeine (400-1000 mg)
Study: 9337609
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of caffeine in excess of daily consumption
Study: 7903212
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tertatolol (T) once daily
Study: 29860937
Drug: Sunitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib alone (50 mg daily in cycles of 28 days on and 14 days off)
Study: 29860937
Drug: Nephrectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nephrectomy followed by sunitinib (50 mg daily in cycles of 28 days on and 14 days off)
Study: 21953134
Drug: Routine occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine occupational therapy
Study: 21356050
Drug: Open reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open reduction and internal fixation (surgical treatment using the Acumed clavicle fixation system)
Study: 11794698
Drug: Clustered dosage
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clustered dosage (5 consecutive daily infusions at 5-week intervals)
Study: 11794698
Drug: Nonclustered dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonclustered dosage (1 infusion weekly)
Study: 24401214
Drug: Intensive rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive rosuvastatin therapy (achieve 30% lower LDL-C levels than standard)
Study: 24401214
Drug: Standard rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rosuvastatin therapy (achieve LDL-C levels recommended by Japanese guidelines)
Study: 23521655
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg.kg(‐1)) and propofol infusion (1.0 μg.ml(‐1) effect-site concentration)
Study: 23521655
Drug: Flumazenil administration
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil administration
Study: 21177169
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg) every night for 3 months in HLT and NLT groups
Study: 14576764
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (exact dosage not specified)
Study: 10553392
Drug: 22-mg, 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg, 24-hour nicotine patch therapy (active patch)
Study: 10553392
Drug: 22-mg, 24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg, 24-hour nicotine patch therapy (open label-pay)
Study: 6683539
Drug: Tablet (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (100 mg)
Study: 6683539
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (100 mg)
Study: 6683539
Drug: Tablets (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (150 mg, 300 mg, 600 mg)
Study: 31771448
Drug: Structured pre-simulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pre-simulation preparation and briefing (35 minutes)
Study: 31771448
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation and briefing
Study: 24246768
Drug: Probiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (1 × 10(8) colony‐forming units, 3 times daily; n = 86)
Study: 22561055
Drug: Oral viscous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral viscous budesonide (OVB) 1 mg twice daily for 8 weeks
Study: 22561055
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (NEB) 1 mg twice daily for 8 weeks
Study: 18632181
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (33.3 mg/m² on days 1, 8, 15 q 4 weeks)
Study: 18632181
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (30 mg/m² on days 1, 8, 15) plus gemcitabine (800 mg/m² on days 1, 8 q 4 weeks) or plus vinorelbine (20 mg/m² on days 1, 8 q 4 weeks)